SLC19A2

Thiamine transporter 1 · O60779 · SLC19A2 on Sugi Atlas →

51 patent compounds predicted against SLC19A2, 33 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Amprolium Ion (SCHEMBL204023)	1.00	1/20
Amprolium Ion (SCHEMBL29737311)	1.00	1/20
Amprolium Ion (SCHEMBL204024)	0.98	1/20
Amprolium Ion (SCHEMBL362893)	0.98	1/20
Amprolium Ion (SCHEMBL20659804)	0.98	1/20
Amprolium Ion (SCHEMBL28047744)	0.98	1/20
Amprolium Ion (SCHEMBL29910331)	0.98	1/20
Amprolium Ion (SCHEMBL363586)	0.95	1/20
Amprolium Ion (SCHEMBL29387363)	0.95	1/20
Amprolium Ion (SCHEMBL1571391)	0.85	1/20
Amprolium Ion (SCHEMBL7107461)	0.83	1/20
Sulfaquinoxaline (SCHEMBL8903136)	0.64	1/20
SCHEMBL9913790	0.63	1/20
Hydrochloric Acid (SCHEMBL10712727)	0.60	1/20
Amprolium Ion (SCHEMBL15436951)	0.59	1/20
Decoquinate (SCHEMBL18227083)	0.53	1/20
SCHEMBL16994846	0.52	1/20
Ampicillin (SCHEMBL1005406)	0.51	1/20
Hydrochloric Acid (SCHEMBL11749235)	0.50	1/20
SCHEMBL10349243	0.48	1/20

Clinical trials — most relevant to SLC19A2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Prevention of Renal Complications of Diabetes With Thiamine	PHASE4	UNKNOWN
The Thiamine Administration After Cardiac Surgery Trial	PHASE4	COMPLETED
High Dose Vitamin B1 to Reduce Abusive Alcohol Use	PHASE4	COMPLETED
Preoperative Parenteral Thiamine Supplementation in Patients Undergoing Heart Surgery	PHASE4	COMPLETED
Optimum Thiamine Intervention (OpTIn) Trial	PHASE4	COMPLETED
Triple Therapy in Septic Shock Patients	PHASE3	COMPLETED
Thiamine as Adjunctive Therapy for Diabetic Ketoacidosis	PHASE2	COMPLETED
The Effect of Thiamine vs. Placebo on VO2 in Critical Illness	PHASE2	COMPLETED
Type 2 Diabetes and Blood Brain Barrier Improvement	EARLY_PHASE1	RECRUITING
Human Tissue Distribution of Orally Supplemented Natural Vitamin E Tocotrienol	EARLY_PHASE1	COMPLETED
The Role of Thiamine After Transcatheter Closure in Children With Left-to-Right Shunt Congenital Heart Disease	EARLY_PHASE1	COMPLETED
Cutaneous Denervation in Alcoholic Neuropathy	nan	UNKNOWN
Oral Thiamine for the Treatment of Painful Diabetic Peripheral Neuropathy	nan	WITHDRAWN
Thiamine As An Adjuvant Therapy For Hyperlactatemia In Septic Shock Patients	nan	UNKNOWN
Epidemiology of Long QTand Asian Sudden Death in Sleep	nan	COMPLETED
SLC13A5 Deficiency Natural History Study - Remote Only	nan	ENROLLING_BY_INVITATION
Thiamine Supplement in Patients With Severe Hyperthyroidism	nan	COMPLETED
Thiamine Administration and Prevalence of Delirium in the Intensive Care Unit: A Before-after Study	nan	COMPLETED
Prevention of Refeeding Syndrome	nan	NOT_YET_RECRUITING
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy	nan	COMPLETED
Effect of Thiamine on Oxygen Utilization (VO2) in Critical Illness	nan	COMPLETED
Supplemental Thiamine in Septic Shock: A Before-after Study	nan	COMPLETED
Vitamin B Therapy for Hyperlactatemia	nan	COMPLETED
Prevalence of Thiamine Deficiency in Hospitalized Non-Alcoholic Veterans	nan	COMPLETED
Thiamine Responsive Disorders (TRD) Among Infants in Lao PDR	nan	COMPLETED
Systemic Inflammatory Response: Thiamine and Magnesium Status (Sir TaM Study)	nan	COMPLETED
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia	nan	RECRUITING
The Effect of a Diet Based on Low Sodium and Slowly Absorbed Carbohydrates on the Incidence of Refeeding Syndrome in Patients With Head and Neck Cancer	nan	COMPLETED
The Prevalence of Thiamin Deficiency in Ambulatory Patients With Heart Failure	nan	COMPLETED
Further Development and Assessment of Tools to Measure Risk Factors for and Treatment of Thiamine Deficiency Disorders	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SLC19A2 binder may also engage these)

Protein	Name	Similarity
Q9EQN9	—	1.000	Q9EQN9 →
Q99PL8	—	0.997	Q99PL8 →
Q9BZV2	—	0.997	Q9BZV2 →
Q4R877	—	0.994	Q4R877 →
P41438	—	0.990	P41438 →
Q62866	—	0.985	Q62866 →
P42557	—	0.981	P42557 →
Q22931	—	0.980	Q22931 →
Q8BSM7	—	0.978	Q8BSM7 →
Q0VCM6	—	0.978	Q0VCM6 →
Q8CGA3	—	0.978	Q8CGA3 →
Q5RF58	—	0.977	Q5RF58 →
Q8N370	—	0.977	Q8N370 →
Q17766	—	0.976	Q17766 →
O45166	—	0.976	O45166 →
SLC43A1	Large neutral amino acids transporter small subunit 3	0.974	landscape →
SLC33A1	Acetyl-coenzyme A transporter 1	0.972	landscape →
SLC19A1	Reduced folate transporter	0.972	landscape →
Q6N075	—	0.971	Q6N075 →
Q6GMG6	—	0.971	Q6GMG6 →
A2AVZ9	—	0.971	A2AVZ9 →
Q1KKV8	—	0.971	Q1KKV8 →
Q8BGK5	—	0.971	Q8BGK5 →
Q5T1Q4	—	0.971	Q5T1Q4 →
Q99J27	—	0.970	Q99J27 →
B0S5Y3	—	0.970	B0S5Y3 →
Q6AYY8	—	0.970	Q6AYY8 →
Q0VC03	—	0.970	Q0VC03 →
A4IHK6	—	0.970	A4IHK6 →
Q4LE88	—	0.970	Q4LE88 →